Intel stock extends gains after report of possible U.S. government stake
GARDEN CITY, N.Y. - Beyond Air, Inc. (NASDAQ:XAIR) reported first quarter revenue that fell short of analyst expectations, sending shares down 16% despite showing strong YoY growth.
The medical device and biopharmaceutical company posted revenue of $1.76 million for the quarter ended June 30, 2025, missing the analyst consensus estimate of $2.06 million. The company reported a loss of -$0.53 per share, significantly wider than the -$0.10 per share analysts had expected. Despite the miss, revenue grew 157% compared to $0.7 million in the same quarter last year and increased approximately 50% sequentially from the previous quarter.
"We are driving strong market adoption of LungFit PH as we continue to break down barriers and expand our global distribution network," said Steve Lisi, Chairman and Chief Executive Officer. "This momentum in our business resulted in strong sequential revenue growth of approximately 50%, to $1.8 million compared with $1.2 million for the March 31, 2025 quarter."
The company reaffirmed its fiscal year 2026 revenue guidance of $12-$16 million, expressing confidence in "sustained double-digit sequential revenue growth." Beyond Air has been expanding its international presence, with distribution agreements now covering over 30 countries and more than 2 billion lives.
Beyond Air also announced it had secured a national group purchasing agreement with Premier, Inc., which has more than 4,350 member hospitals and health systems in its network, potentially expanding the company’s reach in the U.S. market.
The company reported a gross profit of $0.2 million for the quarter, an improvement from a gross loss of $0.3 million in the same period last year. As of June 30, 2025, Beyond Air had $6.5 million in cash, cash equivalents, and marketable securities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.